Cancer Care Ontario | Cancer Care Ontario

You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

69 Results

Statistical Reports

Statistiques 2016 sur le cancer en Ontario

Jun 2016

Drug

niraparib

Other Name(s): Zejula

Quick Link(s):

Drug Monograph, Patient Info Sheet

Mar 2025

Guidelines and Advice

T-Cell Engaging Antibodies: Management of Cytokine Release Syndrome (CRS) and Immune Effector-Associated Neurotoxicity Syndrome (ICANS)

Status: Current

Mar 2025

Guidelines and Advice

Ontario Cervical Screening Program: Interim guidance to support the transition years following the launch of human papillomavirus testing in Ontario: Cervical screening and colposcopy recommendations for people ages 21 to 24

Status: Current

Mar 2025

Guidelines and Advice

An Endorsement of the 2023 International Stereotactic Radiosurgery Society’s (ISRS) Guideline: A Systematic Review Informing the Management of Symptomatic Brain Radiation Necrosis After Stereotactic Radiosurgery and ISRS Recommendations

Status: Current
ID: Guideline Endorsement C50-CIDAP-3

Mar 2025

Guidelines and Advice

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines January to June 2024

Status: Current
ID: PET 2024-1

Mar 2025

Guidelines and Advice

Referral of Suspected Prostate Cancer by Family Physicians and Other Primary Care Providers

Status: In-Review
ID: 24-3
Version: 2

Dec 2016

Guidelines and Advice

Optimization of Surgical and Pathological Quality Performance in Radical Surgery for Colon and Rectal Cancer: Margins and Lymph Nodes

Status: Archived
ID: 17-4
Version: 2

Nov 2016

Guidelines and Advice

Stem Cell Transplantation in the Treatment of Acute Lymphoblastic Leukemia: Recommendations

Status: Archived
ID: SCT 6

Feb 2016

Pages